v3.26.1
Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Financial Performance

Summary segment financial performance measures evaluated by the CODM as of March 31, 2026 and December 31, 2025 and for the three months ended March 31, 2026 and 2025:

 

   March 31, 2026   December 31, 2025 
   Segment Assets 
   March 31, 2026   December 31, 2025 
Digital asset treasury segment  $582,999,512   $513,964,900 
Clinical stage bio-technology segment   1,655,101    5,181,535 
Total assets  $584,654,613   $519,146,435 

 

 

Digital asset treasury segment

 

   2026   2025 
   For the three months ended March 31, 
   2026   2025 
Loss from operations  $(35,221,181)  $- 
Other income (expense) (a)   318,178    - 
Unrealized loss on digital assets holdings   (15,013,304)   - 
Total loss before income taxes  $(49,916,307)  $- 

 

Clinical stage bio-technology segment

 

   2026   2025 
   For the three months ended March 31, 
   2026   2025 
Loss from operations  $(1,647,130)  $(2,546,669)
Other income (expense) (a)   -    4,965 
Total loss before income taxes  $(1,647,130)  $(2,541,704)

 

  (a) Other income (expense) consists of interest income and interest expense.

 

The following table is a reconciliation of segment total loss before income taxes to our consolidated total loss before income taxes.

 

   2026   2025 
   For the three months ended March 31, 
   2026   2025 
Digital asset treasury segment total loss before income taxes  $(49,916,307)  $- 
Clinical stage bio-technology segment total loss before income taxes   (1,647,130)   (2,541,704)
Consolidated total loss before income taxes  $(51,563,437)  $(2,541,704)